What changed
Bio-Rad posted Q3 FY26 adjusted EPS of $2.65, beating consensus of $2.61 by $0.04 (+1.5%). Revenue came in at $656M, up 0.5% YoY (up 0.7% currency-neutral), with Clinical Diagnostics up 2.7% offsetting a 2.8% Life Science decline. FY2026 guidance reiterated at currency-neutral revenue of -3.0% to +0.5% and non-GAAP operating margin of 10.0%-12.0%. The top-line print was led by Clinical Diagnostics growth in quality systems and diabetes products plus strong Droplet Digital PCR demand, while lower process chromatography sales and academic research softness weighed on Life Science.
Why it matters
Bio-Rad posted Q3 FY26 adjusted EPS of $2.65, beating consensus of $2.61 by $0.04 (+1.5%). Revenue came in at $656M, up 0.5% YoY (up 0.7% currency-neutral), with Clinical Diagnostics up 2.7% offsettin